Orthocell
Orthocell is a leader in the regenerative medicine sector, focusing on innovative treatments for chronic degenerative diseases and injuries. The company specializes in developing collagen medical devices and cell therapies that leverage the body's natural repair mechanisms. Orthocell's products are designed to enhance surgical repair and promote tissue regeneration, positioning it as a pioneer in the biotechnology and life sciences industry.
Short position
Orthocell (ASX:OCC) has 0.03% of its shares on issue reported as short positions as of 5 Oct 2026, or about 69,327 shares. Over the past 30 days that figure has fallen 0.24 percentage points, and over 90 days it has fallen 0.34 percentage points. Its highest recorded short interest was 0.94% in December 2025. OCC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Orthocell (OCC) company profile
Profile, insiders and operations
Company
AI-generated research profile of Orthocell
OCC intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links